Andersson M, et al. (2005) Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 25, 8432-8 16162925

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T34-p - DARPP-32 (mouse) ▲

Modsite: MIRRRRPtPAMLFRV SwissProt Entrez-Gene Orthologous residues DARPP‑32 (human): T34‑p, DARPP‑32 iso2 (human): ‑, DARPP‑32 (mouse): T34‑p, DARPP‑32 (rat): T34‑p, DARPP‑32 (cow): T34‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'brain, striatum' [DARPP-32 (mouse)] Comments:  DaRPP-32, DRD2, and ADORA2R KO mice Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CP-55940 increase rimonabant CP-55940 inhibit treatment-induced increase AM404 increase rimonabant AM404 inhibit treatment-induced increase rimonabant no change compared to control CP-55940 DRD2 (mouse) increase CP-55940 ADORA2A (mouse) increase Downstream Regulation Comments:  T34 phosphorylation is required for motor depressant effect.